Hepatitis A virus cellular receptor 2 (HAVCR2) is decreased with viral infection and regulates pro‐labour mediators OA. (3rd May 2017)

• Record Type: Journal Article
• Authors: Liong, Stella; Lim, Ratana; Barker, Gillian; Lappas, Martha
• Is Part Of: American journal of reproductive immunology. Volume 78:Number 1(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-05-03
• Subjects: foetal membranes -- HAVCR2 -- inflammation -- myometrium -- viral infection; Human reproduction -- Immunological aspects -- Periodicals; 616.69206
• DOI: 10.1111/aji.12696
• Languages: English
• ISSNs: 1046-7408

Abstract

Abstract : Problem: Intrauterine infection caused by viral infection has been implicated to contribute to preterm birth. Hepatitis A virus cellular receptor 2 (HAVCR2) regulates inflammation in non‐gestational tissues in response to viral infection. Method of study: The aims of this study were to determine the effect of: (i) viral dsRNA analogue polyinosinic:polycytidylic acid (poly(I:C)) on HAVCR2 expression; and (ii) HAVCR2 silencing by siRNA (siHAVCR2) in primary amnion and myometrial cells on poly(I:C)‐induced inflammation. Results: In human foetal membranes and myometrium, HAVCR2 mRNA and protein expression was decreased when exposed to poly(I:C). Treatment of primary amnion and myometrial cells with poly(I:C) significantly increased the expression and release of pro‐inflammatory cytokines TNF, IL1A, IL1B and IL6 ; the expression of chemokines CXCL8 and CCL2 ; the expression and secretion of adhesion molecules ICAM1 and VCAM1 ; and PTGS2 and PTGFR mRNA expression and the release of prostaglandin PGF2α . This increase was significantly augmented in cells transfected with siHAVCR2. Furthermore, mRNA expression of anti‐inflammatory cytokines IL4 and IL10 was significantly decreased. Conclusion: Collectively, our data suggest that HAVCR2 regulates cytokines, chemokines, prostaglandins and cell adhesion molecules in the presence of viral infection. This suggests a potential for HAVCR2 activators as therapeutics for the management of preterm birth associated with viral infections.